MSN Laboratories – Leader in Innovative Indian Generics
MSN Laboratories
MSN Laboratories Private Limited is a privately held Indian pharmaceutical company founded in 2003 by Dr. Manne Satyanarayana Reddy (MSN Reddy). It is headquartered in Hyderabad, Telangana, and is part of the MSN Group, which the founder leads as chairman and managing director.
MSN makes both active pharmaceutical ingredients, key starting materials and intermediates, and finished dosage forms — tablets, capsules, liquids and injectables. Its portfolio includes generics for oncology, cardiology, endocrinology and other therapy areas.
Oncology is a prominent part of the business. In 2021 the company launched Cabolong, India's first branded generic of cabozantinib for kidney cancer, and in 2023 Palborest, a generic of palbociclib for advanced breast cancer that MSN presented as the world's first generic of this molecule.
In the US, MSN products are sold by its affiliate Novadoz Pharmaceuticals, based in Piscataway, New Jersey. In 2019 the FDA approved MSN's generic trientine hydrochloride 250 mg capsules, equivalent to Syprine. According to the company, its products reach more than 100 countries.
Unifarm carries MSN Laboratories' Cuchel (trientine), a copper chelator for Wilson's disease.